Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
64.56 USD | -0.09% | +0.02% | +238.72% |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 16 | TD Cowen Downgrades Alpine Immune Sciences to Hold From Buy | MT |
Chart calendar Alpine Immune Sciences, Inc.
Upcoming events on Alpine Immune Sciences, Inc.
Past events on Alpine Immune Sciences, Inc.
2024-04-15 04:45 pm | World Congress of Nephrology Meeting |
2024-04-10 05:15 pm | Acquisition of Alpine Immune Sciences Inc by Vertex Pharmaceuticals Incorporated Call |
2024-03-28 03:00 pm | H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference |
2024-03-20 | SLEuro European Lupus Meeting - Poster No:P104 |
2024-03-18 04:30 pm | Q4 2023 Earnings Call |
2024-03-18 04:05 pm | Q4 2023 Earnings Release |
2024-03-12 02:20 pm | Leerink Partners Global Biopharma Conference |
2024-03-04 09:10 am | TD Cowen Health Care Conference |
2024-02-14 12:00 pm | Oppenheimer Healthcare Life Sciences Conference - Fireside Chat |
2024-02-08 10:00 am | Guggenheim Healthcare Talks Biotechnology Conference - Fireside Chat |
2024-01-10 10:30 am | JPMorgan Healthcare Conference |
2023-11-30 07:55 am | Evercore ISI HealthconX Conference |
2023-11-14 04:15 pm | Q3 2023 Earnings Release |
2023-11-14 12:00 pm | American College of Rheumatology Conference - Abstract No 1553950 |
2023-11-12 12:00 pm | American College of Rheumatology Conference - Abstract No 1553700 |
2023-11-03 06:00 pm | American Association of Neuromuscular & Electrodiagnostic Medicine Meeting |
2023-11-02 09:00 pm | American Association of Neuromuscular & Electrodiagnostic Medicine Meeting |
2023-11-02 04:30 pm | Investor Meeting |
2023-11-02 10:00 am | American Society of Nephrology Kidney Conference - Poster No. - TH-PO1125 |
2023-09-13 10:50 am | Morgan Stanley Global Healthcare Conference |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 1,74 0,99 75.14% | 9,34 6,28 48.6% | 23,4 32,9 -28.7% | 30,1 38,3 -21.41% | 58,9 35,7 64.85% | 16,2 |
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | -49,2 -51,5 4.39% | -58,3 -85,7 32% | -43,7 -64,2 31.93% | -120 |
EBIT Million USD | Released Forecast Spread | -43,6 -49,0 10.99% | -28,7 -29,7 3.26% | -49,9 -43,2 -15.52% | -58,1 -56,9 -2.19% | -44,3 -63,4 30.24% | -109 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -41,9 -48,2 13.12% | -27,9 -29,6 5.7% | -50,4 -49,3 -2.24% | -55,4 -49,0 -13.05% | -32,1 -54,1 40.75% | -101 |
Net income Million USD | Released Forecast Spread | -41,9 -48,2 13.12% | -27,9 -29,2 4.35% | -50,3 -43,8 -14.83% | -57,8 -51,1 -13.1% | -32,2 -54,8 41.28% | -101 |
EPS USD | Released Forecast Spread | -2,28 -2,54 10.24% | -1,34 -1,44 6.82% | -1,98 -1,73 -14.45% | -1,73 -1,59 -8.94% | -0,64 -1,07 40.03% | -1,65 |
Announcement Date | 30/03/20 | 18/03/21 | 17/03/22 | 23/03/23 | 18/03/24 | - |
Quarterly results
Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 4,53 14,0 -67.57% | 13,6 16,3 -16.2% | 5,29 10,0 -47.31% | 8,37 18,7 -55.22% | 2,78 11,0 -74.68% | 9,39 6,88 36.44% | 8,59 7,08 21.37% | 10,0 7,25 38.54% | 30,9 9,10 238.89% | 3,52 | 3,49 | 3,50 | 5,22 | 0,00 |
EBITDA Million USD | Released Forecast Spread | -15,2 -17,0 10.36% | -7,31 -14,9 50.95% | -16,3 -17,7 7.72% | -13,7 17,4 -178.64% | -15,5 -16,8 8.02% | -15,5 -17,9 13.34% | -14,4 -17,4 17.22% | 1,70 -15,2 111.15% | -30,3 | -31,6 | -34,0 | -36,6 | ||
EBIT Million USD | Released Forecast Spread | -15,4 -5,90 -160.7% | -7,46 -2,53 -195.01% | -16,5 -10,1 -63.84% | -13,8 -10,8 -28.24% | -20,4 -11,5 -77.27% | -15,6 -17,8 12.35% | -15,7 -19,1 17.83% | -14,6 -17,8 18.17% | 1,55 -15,5 109.99% | -24,9 | -25,4 | -27,3 | -27,3 | -32,6 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -15,5 -14,4 -7.42% | -7,52 -8,58 12.3% | -16,3 -13,6 -19.56% | -13,3 -12,1 -9.82% | -18,3 -11,9 -54.08% | -13,3 -17,5 24.25% | -13,2 -17,7 25.81% | -11,7 -16,5 29% | 6,06 -15,2 139.77% | -24,3 | -25,0 | -27,0 | -25,1 | |
Net income Million USD | Released Forecast Spread | -15,2 -8,68 -74.68% | -7,53 -5,60 -34.39% | -18,1 -12,0 -51.26% | -13,3 -10,8 -23.4% | -18,9 -12,2 -54.69% | -13,3 -17,2 22.74% | -13,2 -17,8 25.95% | -11,7 -16,2 27.46% | 5,96 -16,2 136.89% | -24,0 | -24,8 | -26,8 | -25,7 | |
EPS USD | Released Forecast Spread | -0,52 -0,31 -70.49% | -0,25 -0,19 -33.33% | -0,60 -0,39 -52.87% | -0,42 -0,32 -29.9% | -0,41 -0,27 -52.99% | -0,28 -0,37 24.32% | -0,27 -0,37 26.23% | -0,24 -0,33 26.9% | 0,15 -0,30 150.85% | -0,40 | -0,41 | -0,44 | -0,41 | |
Announcement Date | 17/03/22 | 12/05/22 | 11/08/22 | 14/11/22 | 23/03/23 | 11/05/23 | 14/08/23 | 14/11/23 | 18/03/24 | - | - | - | - | - |
Past sector events for Alpine Immune Sciences, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ALPN Stock
- Calendar Alpine Immune Sciences, Inc.